Atrys Health
Atrys Health is recorded as a service provider in 7 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 7 of 7 trials · Latest update first
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients with Metastatic Breast Cancer (MORPHEUS-panBC)
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2 Trial of RPTR-1-201, a T Cell Receptor Bispecific Therapy, in Advanced Solid Tumors
Sponsor Repertoire Immune Medicines Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase III, Randomized, Open-Label, Multicenter Study of Lurbinectedin in Combination with Atezolizumab Compared with Atezolizumab as Maintenance Therapy in Participants with Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following First-Line Induction Therapy with Carboplatin, Etoposide and Atezolizumab
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
A first-in-human, Phase 1/2, open-label, multi-center, dose-escalation, dose-optimization, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of PARP1-selective inhibitor, EIK1003 (IMP1734), as monotherapy and in combination in participants with advanced solid tumors.
Sponsor Eikon Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, multicenter, open-label study of lifileucel (tumor-infiltrating lymphocytes [TIL]) in participants with previously treated advanced melanoma
Sponsor Iovance Biotherapeutics Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
Phase III, open-label, single-dose, multi-center multinational trial investigating a serotype 5 adeno-associated viral vector containing the Padua variant of a codon-optimized human factor IX gene (AAV5-hFIXco-Padua, AMT-061) administered to adult subjects with severe or moderately severe hemophilia B
Sponsor CSL Behring LLC
- Start (EU)
- Latest update
- Estimated end
A first-in-human, open-label, dose escalation trial with expansion cohorts to evaluate the safety and preliminary efficacy of BNT314 as monotherapy in patients with advanced malignant solid tumors
Sponsor BioNTech SE
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Atrys Health?
The 2026-10-09 snapshot links Atrys Health to 7 distinct CTIS trials. Recorded services include Laboratory services, Specialty lab: PBMC isolation. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Atrys Health?
The most frequently recorded therapeutic areas are Solid Tumor Oncology. Recorded phases include Phase 1, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Atrys Health conducted?
The linked trials record locations in 13 countries, including Spain, Germany, France, Belgium, Denmark. These are trial locations, not confirmed office locations or countries where Atrys Health delivered services.
What can this page tell me about Atrys Health's trial experience?
Browse 7 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Atrys Health. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Atrys Health S.A.